For Pfizer Chief Executive Ian Read the drug companys nearly   is like going back to the future Since  Pfizer has relied on three huge mergers to bolster its top line plug holes in its product portfolio and appease investors But those dealsin which Pfizer acquired WarnerLambert Pharmacia and then Wyethmostly bought time as the drug maker cut costs narrowed its RD focus and then began raising its dividend Since being promoted to CEO three years ago though Mr Read repeatedly has promoted the idea of splitting the drug maker into three separate units and poohpoohed the notion that huge deals would be pursued in order to chase revenue Specific financial details for those entities are in fact due to be released next month